Sokolov 1

Overactive bladder (OAB) is a common health issue affecting many adults, with about 15-20% of the population experiencing it. This research aims to increase awareness and ensure that people with OAB symptoms are correctly referred to specialists such as gynecologists, urogynaecologists, or urologists for proper diagnosis and treatment. The study uses an online screening tool to identify individuals who might have OAB and need specialist evaluation. Participants will use a web platform or mobile app to complete validated questionnaires about their urinary symptoms, personal and family medical history, and quality of life. Those with positive screening results will be referred to a specialist who can access their screening data through the platform, perform further diagnostic tests if needed, confirm or rule out OAB, and decide on appropriate treatment. The study also includes a public relations campaign to encourage participation and improve awareness. During the study, participants will complete the online screening and may attend face-to-face specialist visits for diagnosis. Researchers will monitor the number of participants who complete the screening, the percentage of those with suspected OAB agreeing to follow-up, those diagnosed by specialists, and those who attend follow-up visits up to nine months. The data collected will help evaluate the screening process and its impact on quality of life, with attention to safety and privacy under GDPR.

Researchers are evaluating the safety and effectiveness of a new drug called EIK1001 combined with Pembrolizumab compared to a placebo with Pembrolizumab as the first treatment for patients with advanced melanoma. This is a multicenter, randomized, double-blind Phase 2/3 study that includes dose optimization and an expansion phase. Participants must have advanced melanoma confirmed by tests and be eligible for standard therapy with Pembrolizumab. The study involves two main treatment groups: one receiving EIK1001, a drug that activates immune receptors (TLR 7/8), along with Pembrolizumab, a PD-1 inhibitor, and the other receiving a placebo plus Pembrolizumab. Treatment will be given as first-line therapy, with detailed dose optimization and expansion parts to determine the best dosing. Prior radiotherapy must be completed at least two weeks before starting the study treatment. Participants will undergo regular assessments including imaging scans like CT or MRI to measure tumor response, laboratory tests to check organ function, and monitoring for side effects. Researchers will follow participants for up to five years to track progression-free survival, overall survival, objective response, and adverse events. Women of childbearing potential will have pregnancy tests and must use contraception during and after the study. The total participation time includes screening, treatment, and long-term follow-up to ensure safety and measure outcomes.